A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 33 800 KRW -2.31% Market Closed
Market Cap: 1.6T KRW
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ABL Bio Inc stock under the Base Case scenario is 4 126.71 KRW. Compared to the current market price of 33 800 KRW, ABL Bio Inc is Overvalued by 88%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
4 126.71 KRW
Overvaluation 88%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

50
P/S
P/S
Price to Sales
50
vs History
63
vs Industry
19
Median 3Y
43.2
Median 5Y
68.2
Industry
7.2
Forward
18.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
5
Median 3Y
-28.5
Median 5Y
-23.9
Industry
21.4
Forward
-169.7
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
2
Median 3Y
13.8
Median 5Y
-21.1
Industry
20.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
1
Median 3Y
15
Median 5Y
-19.2
Industry
24.5
More Details
10
P/B
P/B
Price to Book Value
10
vs History
74
vs Industry
8
Median 3Y
13.8
Median 5Y
12.3
Industry
2.4
More Details
46
EV/S
EV/S
Enterprise Value to Sales
46
vs History
65
vs Industry
17
Median 3Y
40.3
Median 5Y
68.6
Industry
7.4
Forward
17.8
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
3
Median 3Y
-25.5
Median 5Y
-21.4
Industry
4.1
Forward
-175.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
3
Median 3Y
-23.9
Median 5Y
-20.7
Industry
3.8
Forward
-882.8
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
2
Median 3Y
13.3
Median 5Y
-20.3
Industry
5.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
1
Median 3Y
14
Median 5Y
-18.9
Industry
3.3
More Details
16.8
EV/IC
EV/IC
Enterprise Value to IC
16.8
vs History
52
vs Industry
13
Median 3Y
13.2
Median 5Y
18.2
Industry
4.4
More Details

Multiples Across Competitors

Competitors Multiples
ABL Bio Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
ABL Bio Inc
KOSDAQ:298380
1.7T KRW 50 -30.1 -27 -25.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 908 785.7 -175 422 -213 018.2 -210 587.4
US
Abbvie Inc
NYSE:ABBV
355.3B USD 6.3 83.8 16.5 24.9
US
Amgen Inc
NASDAQ:AMGN
164.1B USD 4.9 40.1 16.2 28.8
US
Gilead Sciences Inc
NASDAQ:GILD
136.2B USD 4.7 283.6 11.1 14
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.5B USD 11.7 -240 26.3 27.5
US
Epizyme Inc
F:EPE
94.1B EUR 1 908.7 -487.1 -530.4 -516.3
AU
CSL Ltd
ASX:CSL
122.2B AUD 5.1 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
70.2B USD 4.9 15.9 10.3 11.5
US
Seagen Inc
F:SGT
39.3B EUR 18.4 -56.4 -60.6 -54.7
NL
argenx SE
XBRU:ARGX
32.6B EUR 16 42 309.4 -2 279.4
P/S Multiple
Revenue Growth P/S to Growth
KR
A
ABL Bio Inc
KOSDAQ:298380
Average P/S: 3 355 528.8
50
-11%
N/A
FR
Pharnext SCA
OTC:PNEXF
36 908 785.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.3
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.7
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
E
Epizyme Inc
F:EPE
1 908.7
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.9
7%
0.7
US
S
Seagen Inc
F:SGT
18.4
30%
0.6
NL
argenx SE
XBRU:ARGX
16
37%
0.4
P/E Multiple
Earnings Growth PEG
KR
A
ABL Bio Inc
KOSDAQ:298380
Average P/E: 82.3
Negative Multiple: -30.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -175 422 N/A N/A
US
Abbvie Inc
NYSE:ABBV
83.8
88%
1
US
Amgen Inc
NASDAQ:AMGN
40.1
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
283.6
185%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -240 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -487.1 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.4 N/A N/A
NL
argenx SE
XBRU:ARGX
42
19%
2.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
A
ABL Bio Inc
KOSDAQ:298380
Average EV/EBITDA: 58.2
Negative Multiple: -27 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -213 018.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.2
17%
1
US
Gilead Sciences Inc
NASDAQ:GILD
11.1
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.3
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.6 N/A N/A
NL
argenx SE
XBRU:ARGX
309.4
166%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
A
ABL Bio Inc
KOSDAQ:298380
Average EV/EBIT: 21.4
Negative Multiple: -25.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 587.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.9
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
28.8
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.5
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.5
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 279.4 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 241,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.